BACKGROUND: Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia. OBJECTIVE: To examine the effect of nelfinavir on pravastatin pharmacokinetics. DESIGN: Open-label study in healthy HIV-seronegative adults conducted at the AIDS Clinical Trials Group sites in the United States. METHODS: Subjects received pravastatin 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Subjects took only nelfinavir 1250 mg twice daily on days 4-12. On days 13-15, subjects continued nelfinavir and reinitiated pravastatin. Plasma samples were collected over 24 h for the calculation of pravastatin area under the concentration-time curve for 0-24 h on days 3 and 16. RESULTS: Data from 14 subjects with complete pharmacokinetic samples were available for analysis. The median within-subject percentage change in pravastatin AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were also lower when pravastatin was administered with nelfinavir. Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%. CONCLUSIONS: Coadministration of pravastatin and nelfinavir led to a substantial reduction in pravastatin plasma concentrations. Higher doses of pravastatin may need to be prescribed in order to achieve optimal lipid-lowering activity.
BACKGROUND:Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia. OBJECTIVE: To examine the effect of nelfinavir on pravastatin pharmacokinetics. DESIGN: Open-label study in healthy HIV-seronegative adults conducted at the AIDS Clinical Trials Group sites in the United States. METHODS: Subjects received pravastatin 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Subjects took only nelfinavir 1250 mg twice daily on days 4-12. On days 13-15, subjects continued nelfinavir and reinitiated pravastatin. Plasma samples were collected over 24 h for the calculation of pravastatin area under the concentration-time curve for 0-24 h on days 3 and 16. RESULTS: Data from 14 subjects with complete pharmacokinetic samples were available for analysis. The median within-subject percentage change in pravastatin AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were also lower when pravastatin was administered with nelfinavir. Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%. CONCLUSIONS: Coadministration of pravastatin and nelfinavir led to a substantial reduction in pravastatin plasma concentrations. Higher doses of pravastatin may need to be prescribed in order to achieve optimal lipid-lowering activity.
Authors: John G Gerber; Susan L Rosenkranz; Carl J Fichtenbaum; Jose M Vega; Amy Yang; Beverly L Alston; Susan W Brobst; Yoninah Segal; Judith A Aberg Journal: J Acquir Immune Defic Syndr Date: 2005-07-01 Impact factor: 3.731
Authors: Steven G Simonson; Ali Raza; Paul D Martin; Patrick D Mitchell; John A Jarcho; Colin D A Brown; Amy S Windass; Dennis W Schneck Journal: Clin Pharmacol Ther Date: 2004-08 Impact factor: 6.875
Authors: Sudershan Singh; James H Willig; Michael J Mugavero; Paul K Crane; Robert D Harrington; Robert H Knopp; Bradley W Kosel; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: Clin Infect Dis Date: 2010-12-28 Impact factor: 9.079
Authors: Carlos D Malvestutto; Qing Ma; Gene D Morse; James A Underberg; Judith A Aberg Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Jialin Mao; Utkarsh Doshi; Matthew Wright; Cornelis E C A Hop; Albert P Li; Yuan Chen Journal: CPT Pharmacometrics Syst Pharmacol Date: 2018-02-13